ASS1 and neoplasm: A subsequent phase 2 clinical trial in soft-tissue sarcoma using ADI-PEG20, gemcitabine, and docetaxel has been completed, with preliminary data showing safety with a reduced dose of gemcitabine consistent with the mechanistic data, and a trend for greater benefit in patients with ASS1-negative tumours (ClinicalTrials.gov, NCT03449901 [63]); an additional study of this triplet is proceeding in relapsed non-small cell lung cancer and small cell lung cancer (ClinicalTrials.gov, NCT05616624).